1. Home
  2. GLTO vs MDIA Comparison

GLTO vs MDIA Comparison

Compare GLTO & MDIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Galecto Inc.

GLTO

Galecto Inc.

HOLD

Current Price

$30.40

Market Cap

54.5M

Sector

Health Care

ML Signal

HOLD

Logo Mediaco Holding Inc.

MDIA

Mediaco Holding Inc.

HOLD

Current Price

$0.62

Market Cap

52.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLTO
MDIA
Founded
2011
2019
Country
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Broadcasting
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
54.5M
52.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GLTO
MDIA
Price
$30.40
$0.62
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$43.67
N/A
AVG Volume (30 Days)
257.7K
146.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.01
$0.54
52 Week High
$38.33
$1.60

Technical Indicators

Market Signals
Indicator
GLTO
MDIA
Relative Strength Index (RSI) 61.02 40.62
Support Level $19.85 $0.57
Resistance Level $32.56 $0.65
Average True Range (ATR) 3.15 0.04
MACD 0.62 -0.00
Stochastic Oscillator 86.55 32.73

Price Performance

Historical Comparison
GLTO
MDIA

About GLTO Galecto Inc.

Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

About MDIA Mediaco Holding Inc.

MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment. The company generates the majority of its revenue from the Audio segment.

Share on Social Networks: